Monitor patient enrollment updates and any further capital raises. The stock is highly volatile with low liquidity; the clinical catalyst timeline (first patient dosing) will be the next major event, but the dilutive structure and going-concern risk suggest continued downside pressure.
Price Chart
Executive Summary
Silexion Therapeutics reported Q2 2026 net loss of $3.6M (vs $2.5M a year ago) and EPS of -$8.50, far below the -$2.12 consensus, though the miss is largely mechanical for a pre-revenue biotech. The company is advancing SIL204 into a Phase 2/3 trial but burned through cash, ending June with $2.2M in cash and recently raising $2.5M in a dilutive public offering. The clinical progress is offset by widening losses, going-concern risk, and severe dilution.
Key Financial Metrics
Key Facts
- Net loss for Q2 2026 was $3.6M, up 44% from $2.5M in Q2 2025.
- EPS was -$8.50 vs consensus of -$2.12, a 300.9% miss.
- Cash and cash equivalents fell to $2.2M as of June 30, 2026, from $6.0M at year-end 2025.
- Company raised $2.5M gross in a public offering on August 13, 2026, highly dilutive at ~$1M market cap.
- Phase 2/3 trial of SIL204 initiated at Tel Aviv Sourasky Medical Center in July 2026.
Financial Impact
Net loss increased 44% YoY to $3.6M; cash burn rate accelerating; $2.5M dilutive offering adds ~$2.1M net proceeds.
Risk Factors
- Going-concern risk: cash of $2.2M (plus $2.1M net from recent offering) may not fund full Phase 2/3 trial.
- Severe dilution: recent public offering at $0.65/share adds ~3.8M shares, massively diluting existing holders.
- Nasdaq listing risk: required shareholders' equity of $2.5M is barely met with estimated $3.2M post-offering.
- Clinical execution risk: no guarantee of successful patient enrollment or positive data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345339 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1660 (−7.93%) |
Oct 5, 2026 22d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1660 (+36.83%) |
Sep 30, 2026 27d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1660 (−40.07%) |
Sep 30, 2026 27d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1660 (+40.14%) |
Sep 29, 2026 28d ago | 8-K | $0.3180 $0.1650 | ▲ +48.11% | ▲ +48.77% | $0.1660 (+47.80%) |
Sep 29, 2026 28d ago | Press Release | $0.3184 $0.1657 | ▲ +47.96% | ▲ +48.67% | $0.1660 (+47.86%) |
Sep 28, 2026 29d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1660 (−33.17%) |
Sep 28, 2026 29d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1660 (−33.17%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1660 (+33.17%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1660 (+60.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers